Trinity Biotech plc (TRIB) AI Stock Analysis

Trinity Biotech plc specializes in the acquisition, development, manufacturing, and global distribution of medical diagnostic products catering to clinical laboratory and point-of-care markets across the Americas, Africa, Asia, and Europe. Its diagnostic tests and instrumentation detect infectious diseases such as Lyme disease, syphilis, herpes, SARS-CoV-2, Epstein Barr virus, measles, mumps, and rubella. The company also supplies in-vitro diagnostic tests for hemoglobin A1c to monitor diabetes. Additionally, Trinity Biotech manufactures assay formats including ELISA and western blot, produces reagent products for liver and kidney disease diagnostics, and provides raw materials to research institutes and life sciences partners.

Revenue contracted at a 5-year CAGR of -15.6% from FY2020 to FY2025. After generating $81.1M in FY2021 with net income of $875,000, revenue fell 23.0% in FY2022 to $62.5M with a net loss of -$41.0M. Revenue reached $56.8M in FY2023 before rising 8.3% to $61.6M in FY2024. In FY2025, revenue fell 28.9% to $43.8M, gross margin stood at 38.6%, operating margin was -26.1%, and net loss was -$37.4M. In the latest quarter ended March 31, 2026, quarterly revenue fell 5.5% year-over-year, while quarterly earnings declined 77.3%.

As of March 31, 2026, Trinity Biotech held $5.1M in cash and short-term investments against $138.0M in total debt, resulting in net debt of $132.8M. Shareholders' equity was -$72.0M with total assets of $105.2M, and the current ratio stood at 0.25. The company posted negative operating cash flow of -$5.9M and free cash flow of -$12.2M in FY2025, while spending $6.2M on capital expenditures. Over the past five years, its share count expanded by 254.4%.

Trinity Biotech has a market capitalization of $6.5M and an enterprise value of $138.9M. Its forward P/E is 4.5x, well below the 17.3x median of its US-listed Healthcare peers. Its price-to-sales multiple is 0.1x compared to the peer median of 4.1x, and its EV-to-revenue multiple is 3.2x. Over the past year, the stock dropped 73.9%, while the S&P 500 (SPY) gained 16.8%. Over five years, the stock is down 97.4% compared to an 83.0% gain for SPY.

The mean price target from 1 analyst following Trinity Biotech is $3.00, implying downside of 62.6% from the last close of $8.03. For the next fiscal year, the analyst models revenue of $59.5M, reflecting 25.3% growth, alongside an EPS estimate of -$1.09, which represents 38.4% growth. Over the last four quarters, the company beat EPS estimates once.

This page is an AI-written research summary of Trinity Biotech plc (TRIB). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: TRIB income statement, TRIB balance sheet, TRIB key metrics, TRIB analyst forecast, TRIB chart. See the TRIB stock overview for the latest quote and news.